FORMULATION AND EVALUATION OF FAST DISSOLVING TABLETS OF ETORICOXIB

Fast dissolving tablet format is designed to allow administration of an oral solid dose form in the absence of water or fluid intake. Such tablets readily dissolve or disintegrate in the saliva. Currently it is approved in more than 60 countries worldwide. Etoricoxib is a COX-2 selective inhibitor. Current therapeutic indications of Etoricoxib are rheumatoid arthritis, psoriatic arthritis, osteo arthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Like any other COX-2 selective inhibitor, so those to treat the above diseases and to get quick action oral fast disintegrating tablets were prepared. The aim of this research is the development of fast dissolving tablet of Etoricoxib, to overcome solubility problem of Etoricoxib. Dissolution of Etoricoxib enhanced by solid dispersion technique in which Etoricoxib-carrier β-cyclodextrin solid dispersion were prepared by solvent evaporation technique, in three molar rations (1:1, 1:2 and 1:3).In formulation Croscarmellose sodium and Crospovidone used to maintain rapid disintegration. Preparation of tablet by direct compression and evaluation were done. In vitro and In vivo taste evaluation was done. Compatibility between drug and excipient examine by FTIR study.